However, the majority of existing LRRK2 inhibitors, including DNL201 and PF‐06447475, have predominantly been investigated in models of LRRK2 mutant PD models,4, 32 where the effect of LRRK2 may be different from that in sporadic PD. This evidence concerns the gene LRRK2 and Parkinson disease.